Drug Combo Proves Powerful Against Lung Cancer Huntington NY

A two-drug combination treatment in Huntington proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

IRUM CHAUDHRY, MD
(516) 965-1112
131 Marcellus Road
Mineola, NY
Eva Chalas, MD
631-864-5440
1077 W Jericho Tpke
Smithtown, NY
Jagmohan K Kalra, MD
516-358-7700
2001 Marcus Ave Ste S20
New Hyde Park, NY
Mark David Lipshutz, MD
631-666-6752
24 E Main St
Bay Shore, NY
Paul Leslie Weinstein, MD
203-325-2695
34 Shelburne Rd
Stamford, CT
Rosann Catherine Dalessandro
(631) 427-6060
347 Main St
Huntington, NY
SHARON SINGH, MD
(718) 470-3460
26901 76Th Avenue
New Hyde Park, NY
Steven A Montana, DO
631-751-8305
2500 Nesconset Hwy Bldg 26 Ste 90
Stony Brook, NY
Myles Ralph Desner, MD
516-354-5700
71 Karol Pl
Jericho, NY
Dwight Carlton De Risi, MD
516-487-8888
1010 Northern Blvd Ste 140
Great Neck, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Risks for Childhood Cancer Survivors Huntington NY
People who survived cancer as children face a high lifelong risk for developing another cancer, a new study has found. A study that appears online May 26 in the Journal of the National Cancer Institute went further than earlier studies by following people from birth through age 79. The researchers analyzed data on more than 47,000 people who had been diagnosed with cancer before the age of 20.
- Side Effect Of Chemotherapy Drugs Huntington NY
- Exercise for Prostate Cancer Huntington NY
- Hormone Therapy for Breast Cancer Huntington NY
- Exercise for Breast Cancer Survival Huntington NY
- Fungal Infection Treatments Huntington NY
- Genetic Clues for Skin Cancer Therapies Huntington NY
- Hormone Therapy for Lung Cancer Huntington NY
- Delayed Prostate Cancer Therapy Huntington NY